Circadian Clock Predicts Cancer Therapy Effectiveness
New Data Highlights Potential of Epcoritamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Table of Contents
New data presented at teh 2024 ASCO Annual Meeting are bolstering the promise of epcoritamab-bysp (Epkinly) as a treatment option for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The data, from the pivotal phase 3 EPCORE NHL-1 trial, demonstrate sustained remissions and a manageable safety profile, even in patients who have failed prior CAR T-cell therapy.
Epcoritamab: A Novel Approach to DLBCL Treatment
DLBCL is an aggressive type of non-Hodgkin lymphoma. While many patients achieve initial remission with chemotherapy, a meaningful proportion experience relapse or become refractory to standard treatments. This leaves a critical unmet need for effective therapies.
Epcoritamab represents a novel approach. Its a bispecific antibody that simultaneously binds to CD20, found on lymphoma cells, and CD3, found on T cells. This dual action brings T cells into close proximity with lymphoma cells, activating the T cells to kill the cancer cells. Unlike CAR T-cell therapy,epcoritamab is an off-the-shelf treatment,meaning it doesn’t require patient-specific cell manufacturing,offering quicker access to therapy.
EPCORE NHL-1 Trial: Key Findings
The EPCORE NHL-1 trial enrolled patients with R/R DLBCL who had previously received at least two lines of systemic therapy. the trial compared epcoritamab to standard of care, which included investigator’s choice of chemotherapy regimens.
Here’s a breakdown of the key findings presented at ASCO:
Superior Overall Response Rate (ORR): Patients treated with epcoritamab demonstrated a significantly higher ORR (63%) compared to those receiving standard of care (32%). This means a greater proportion of patients experienced a reduction in their tumor size.
complete Response Rate (CRR): A considerable 32% of patients on epcoritamab achieved a complete response, meaning all signs of cancer disappeared, compared to only 15% in the standard of care arm.
Durable Remissions: The median duration of response for patients achieving a complete response was not yet reached at the time of the ASCO presentation, suggesting long-lasting benefits.
Activity After CAR T-Cell Therapy: Importantly, epcoritamab showed activity even in patients who had previously failed CAR T-cell therapy, a population with limited treatment options. The ORR in this subgroup was 39%.
* Manageable Safety Profile: While epcoritamab can cause cytokine release syndrome (CRS),a common side effect of immunotherapies,the majority of CRS events were low grade and manageable with supportive care. neurologic events were infrequent.
What This Means for Patients
These results are encouraging for patients with R/R DLBCL.Epcoritamab offers a new, effective treatment option, notably for those who have tired other therapies. The fact that it’s an off-the-shelf therapy is a significant advantage,possibly shortening the time to treatment.
“These data reinforce epcoritamab’s potential to transform the treatment landscape for patients with relapsed or refractory DLBCL,” said dr. Olivia Walch, lead investigator of the EPCORE NHL-1 trial, in a press release. “the sustained remissions and manageable safety profile observed in this trial are particularly encouraging.”
Looking Ahead
Epcoritamab has already received accelerated approval from the FDA for the treatment of R/R DLBCL. The full results from the EPCORE NHL-1 trial are expected to support a potential full approval. Researchers are also exploring the use of epcoritamab in earlier lines of therapy and in combination with other treatments.
If you or someone you know is facing